MyFinsight
Home
Blog
About
Maturities of short-term
investments
$75,000K
(-9.64%↓ Y/Y)
Proceeds from employee
stock purchase plan...
$455K
(157.06%↑ Y/Y)
Proceeds from issuance of
common stock, net...
$56K
(-99.94%↓ Y/Y)
Net cash used in
investing activities
$5,953K
(113.01%↑ Y/Y)
Net cash provided by
financing activities
$511K
(-99.45%↓ Y/Y)
Canceled cashflow
$69,047K
Net increase in
cash, cash...
-$11,604K
(-205.59%↓ Y/Y)
Canceled cashflow
$6,464K
Deferred revenue
$35,835K
(158.01%↑ Y/Y)
Accrued liabilities and
other long-term...
$3,338K
(204.02%↑ Y/Y)
Stock-based compensation
expense
$2,577K
(-25.07%↓ Y/Y)
Non-cash lease expense
-$1,365K
(37.64%↑ Y/Y)
Accounts payable
$571K
(166.94%↑ Y/Y)
Amortization of intangible
assets
$36K
(-50.68%↓ Y/Y)
Depreciation and
amortization
$11K
(-98.33%↓ Y/Y)
Purchases of short-term
investments
$69,047K
(-46.32%↓ Y/Y)
Net cash used in
operating activities
-$18,068K
(50.90%↑ Y/Y)
Canceled cashflow
$43,733K
Accounts receivable
$36,848K
(3086.06%↑ Y/Y)
Net income (loss)
-$20,666K
(-188.43%↓ Y/Y)
Prepaid expenses and
other assets
$2,859K
(165.71%↑ Y/Y)
Accretion of discounts on
short-term investments
$1,428K
(67.80%↑ Y/Y)
Back
Back
Cash Flow
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)
source: myfinsight.com